InvestorsHub Logo
icon url

breathofthenightwind

05/17/20 12:49 PM

#274269 RE: HinduKush #274243

HinduKush, you cannot just import scientific standards of evidence into a legal proceeding. Yes, in cases like Amarin’s patent battle with the generics, science plays a role. But the law has its own standards, for its own purposes, and in the end legal standards control. It is a mistake to judge Mori by the standards of peer review science and then assume that your conclusions in that respect will control how Mori functions in an obviousness analysis.

“In the Amarin appeal case the CAFC must somehow be induced to re-examine the Du process of determining prima facie obviousness or risk overlooking the egrey intellectual errors of logic and reasoning that lead to an erroneous conclusion.”

They will re-examine Judge Du’s factual findings, but under a clearly erroneous standard.

I think you are wrong about the patent examiner. The Amarin patents were allowed by the USPTO based on secondary considerations of non-obviousness, right? Not on the basis of failure of the prior art as a whole to create a prima facie case of obviousness.
icon url

concapk

05/17/20 1:32 PM

#274287 RE: HinduKush #274243

OBVIOUSNESS

It can be assumed that in MORI that ldl raised up by 3.5% using EPA which was not stag significant, but all studies prior reflected increased ldl the higher your tri's increased... since all studies prior were for tri's lower than 500 and LOVAZA was for TRI'S over 500 that increased ldl and people with tri's over 500 had genentic problems ...how could you ANTICIPATE that pure EPA would NOT increase LDL.... YOU would assume as SINGER points out that Judge Du's ASSUMPTIONS are nor clear...